Developmentally programmed pediatric sarcomas: a versatile platform for drug discovery and molecular precision medicine
The project aims to develop innovative in vitro and in vivo models of Ewing sarcoma using human pluripotent stem cells to enhance drug discovery and precision medicine for pediatric cancers.
Projectdetails
Introduction
Pediatric sarcomas account for ~20% of childhood cancers. They have disappointing survival rates, with very little therapeutic progress over the last three decades. We clearly have to rethink the science and find new ways to tackle these devastating tumors. I propose that new cellular models are needed that account for the developmental origins of pediatric sarcoma, in order to accelerate drug discovery and molecular precision medicine.
Focus on Ewing Sarcoma
Focusing on Ewing sarcoma, which is a developmental cancer caused by a (known) fusion oncogene expressed in (unknown) cells-of-origin, we will pursue a “build it to understand it” approach and construct in vitro and in vivo tumor models starting from human pluripotent stem cells (hPSCs).
Model Validation
We will validate these models against our single-cell and spatial maps of Ewing sarcoma tumors, and we will pursue initial applications in academic drug discovery, including:
- Targeting the regulatory programs of Ewing sarcoma cells
- Investigating metabolic dependencies of the tumor microenvironment
- Studying developmentally programmed tumors in their in vivo context
Building Ewing Sarcoma Models
To build Ewing sarcoma models in a molecularly defined manner, we will:
- Map oncogene-competent cell states by inducing EWS-FLI1 expression in hPSC-based models of human development (Aim 1).
- Create supportive tumor microenvironments by 3D differentiation and CRISPR screening in stromal cells (Aim 2).
- Evaluate the ability of in vitro models to form tumors in mice, and pursue full in vivo modeling of Ewing sarcoma using genetically engineered teratomas (Aim 3).
Comparison with Existing Models
Compared to patient-derived xenografts, organoids, or cell lines, our approach captures early events of tumorigenesis, providing complementary in vitro and in vivo models of Ewing sarcoma for biomedical and translational research.
Generalization to Other Tumor Types
This approach will generalize to other tumor types, as it takes the concept of developmental cancers seriously and operationalizes it using cellular programming and high-throughput functional biology.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 1.999.124 |
Totale projectbegroting | € 1.999.124 |
Tijdlijn
Startdatum | 1-10-2023 |
Einddatum | 30-9-2028 |
Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- ST. ANNA KINDERKREBSFORSCHUNG GMBHpenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Deciphering non-genetic determinants and targetability of cancer cell plasticity.This project aims to reverse cancer cell plasticity in pediatric tumors using advanced genomic techniques to develop new therapeutic strategies for effective treatment. | ERC Consolid... | € 2.000.000 | 2025 | Details |
Targeting the undruggable: Leveraging neomorphic DNA-binding preferences of chimeric fusion oncogenes to promote cancer suicideThis project aims to develop a novel viral vector strategy that leverages oncogenic transcription factors to selectively induce cancer cell suicide in aggressive tumors like Ewing sarcoma. | ERC Consolid... | € 1.992.235 | 2024 | Details |
Oncogenic competence during development – When, Where and Why?This project aims to uncover the origins and transformation mechanisms of malignant rhabdoid tumors through advanced genomic and imaging techniques, with the goal of developing targeted treatments. | ERC Starting... | € 1.499.943 | 2023 | Details |
Decoding and Targeting Treatment-Resistant Metastatic NeuroblastomaThis project aims to develop advanced models to study treatment resistance in neuroblastoma, identify novel therapeutic targets, and validate combination therapies for relapsed cases. | ERC Consolid... | € 2.000.000 | 2024 | Details |
Precision Lethality to overcome clonal heterogeneity in high-risk neuroblastomaThis project aims to develop precision lethality methodologies using cell barcoding to identify effective drug combinations for treating neuroblastoma, overcoming clonal heterogeneity. | ERC Starting... | € 1.497.981 | 2024 | Details |
Deciphering non-genetic determinants and targetability of cancer cell plasticity.
This project aims to reverse cancer cell plasticity in pediatric tumors using advanced genomic techniques to develop new therapeutic strategies for effective treatment.
Targeting the undruggable: Leveraging neomorphic DNA-binding preferences of chimeric fusion oncogenes to promote cancer suicide
This project aims to develop a novel viral vector strategy that leverages oncogenic transcription factors to selectively induce cancer cell suicide in aggressive tumors like Ewing sarcoma.
Oncogenic competence during development – When, Where and Why?
This project aims to uncover the origins and transformation mechanisms of malignant rhabdoid tumors through advanced genomic and imaging techniques, with the goal of developing targeted treatments.
Decoding and Targeting Treatment-Resistant Metastatic Neuroblastoma
This project aims to develop advanced models to study treatment resistance in neuroblastoma, identify novel therapeutic targets, and validate combination therapies for relapsed cases.
Precision Lethality to overcome clonal heterogeneity in high-risk neuroblastoma
This project aims to develop precision lethality methodologies using cell barcoding to identify effective drug combinations for treating neuroblastoma, overcoming clonal heterogeneity.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Next-Generation Drug Discovery Platform for Targeting Cancer Stem Cell PathwaysDevelop a drug discovery platform using patient-derived organoids and machine learning to target stem cell signaling pathways in colorectal cancer, aiming to improve treatment outcomes. | EIC Transition | € 2.433.125 | 2022 | Details |
Next-Generation Drug Discovery Platform for Targeting Cancer Stem Cell Pathways
Develop a drug discovery platform using patient-derived organoids and machine learning to target stem cell signaling pathways in colorectal cancer, aiming to improve treatment outcomes.